Cargando…
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
Multiple sclerosis (MS) is among the most common chronic inflammatory diseases of the central nervous system. Although not curable, the constantly increasing armamentarium of disease-modifying drugs now allows control of disease activity in many patients. The humanized monoclonal antibody alemtuzuma...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076850/ https://www.ncbi.nlm.nih.gov/pubmed/27799738 http://dx.doi.org/10.2147/DDDT.S97956 |